TNF inhibitors may reduce fracture risk 29% vs NSAIDs in axial spondyloarthritis

Share on social media

Healio featured Foundation-funded investigator Maureen Dubreuil, MD, MSc in a story about how her study may help reduce risk for hip or spine fractures in patients living with spondyloarthritis patients.

Axial spondyloarthritis patients are at a higher risk of experiencing hip and spine fractures that cause a lot of pain and complications. Maureen Dubreuil, MD, MSc and her colleagues conducted a study that discovered that TNF inhibitors may decrease the risk for hip or spine fracture by 29% in the treatment of patients with axial spondyloarthritis when compared with NSAIDs. This finding could be an important consideration for patients and their clinicians when developing a treatment plan.

This finding could impact patients with axial SpA by:

  • Reducing fracture risk
  • Improving treatment decision-making
  • Offering a better overall quality of life and fewer complications from fractures

This work was partly supported by the Rheumatology Research Foundation. Maureen Dubreuil, MD, MSc, a 2023 Career Development Bridge Funding Award: R Bridge recipient, led a project titled Back Pain Phenotypes: Imaging, Genetics and Outcome Associations Among Rural Residents of the United States.

Read more here